Brind.
  1. MarketBeat used its screener tool to monitor financial health on June 10, 2026.
  2. Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.

Intuitive Surgical is developing and marketing its da Vinci product line and Ion Endoluminal system in the US market.

6 reports, 4 independent Updated Jul 21
Gone quiet Reached 3 outlets in its first 24 hours
Reports
6
Developments
4
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Intuitive Surgical is developing and marketing its da Vinci product line and Ion Endoluminal system in the US market.

Who's involved

What this event is mainly about
ION

How it developed

Newest first. Tap a step to see who reported it.
  1. Intuitive announced specific uses for its da Vinci and Ion systems.1 source
  2. FDA cleared the first da Vinci system for Intuitive Surgical on August 21, 2025.Sub-event
  3. Intuitive Surgical is developing and marketing its da Vinci and Ion systems in the US.1 source
  4. ION is expanding into Korea, while competing with Stryker and Intuitive Surgical in the robotic bronchoscopy space.1 source

Keep exploring

Part of

Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector. All 1 developments

Within MarketBeat used its screener tool to monitor financial health on June 10, 2026.

The entities involved

Coverage

Newest first; wire copies grouped
  • fool.com
  • yahoo.com
  • StockStory2 Cash-Heavy Stocks to Consider Right Now and 1 We Find Risky Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage
  • ZacksISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency Intuitive Surgical’s ISRG Ion platform continues to build momentum, posting a robust 52% year-over-year improvement in procedures (to a
  • ZacksCan ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside? Intuitive Surgical ISRG delivered a solid second-quarter 2025 performance, with procedure volumes up 17% year over year, maint
  • Unknown outlet